Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Callréus, Torbjörn ; El-Galaly, Tarec Christoffer ; Jerkeman, Mats ; de Nully Brown, Peter ; Andersen, Morten. / Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases. I: Pharmaceutical Medicine. 2019 ; Bind 33, Nr. 2. s. 83-88.

Bibtex

@article{bb4b78edf98b43a7b24659b47c963a9d,
title = "Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases",
abstract = "Following intense research efforts, modulation of the immune system has finally proved to be a viable approach for treating malignant disease. Recently, chimeric antigen receptor redirected T cells have achieved promising outcomes in patients with B-cell malignancies and they are currently also being investigated in other haematological malignancies, solid tumours and viral infections. Compared with traditional biopharmaceuticals, the properties of genetically modified chimeric antigen receptor redirected T-cell therapies differ in many aspects, thereby posing challenges in terms of post-authorisation data collection and data analysis. We believe that the network of population-based Nordic healthcare databases has some characteristics that can help provide important data on these new types of advanced products. In particular, the possibility of very long follow-up periods with a limited loss to follow-up is an important strength. Given the limited source population and slow access to data, a Nordic chimeric antigen receptor redirected T-cell monitoring project should be seen as complementary to other surveillance initiatives.",
author = "Torbj{\"o}rn Callr{\'e}us and El-Galaly, {Tarec Christoffer} and Mats Jerkeman and {de Nully Brown}, Peter and Morten Andersen",
year = "2019",
month = apr,
doi = "10.1007/s40290-019-00270-7",
language = "English",
volume = "33",
pages = "83--88",
journal = "Journal of Pharmaceutical Medicine",
issn = "0731-7085",
publisher = "Elsevier BV",
number = "2",

}

RIS

TY - JOUR

T1 - Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases

AU - Callréus, Torbjörn

AU - El-Galaly, Tarec Christoffer

AU - Jerkeman, Mats

AU - de Nully Brown, Peter

AU - Andersen, Morten

PY - 2019/4

Y1 - 2019/4

N2 - Following intense research efforts, modulation of the immune system has finally proved to be a viable approach for treating malignant disease. Recently, chimeric antigen receptor redirected T cells have achieved promising outcomes in patients with B-cell malignancies and they are currently also being investigated in other haematological malignancies, solid tumours and viral infections. Compared with traditional biopharmaceuticals, the properties of genetically modified chimeric antigen receptor redirected T-cell therapies differ in many aspects, thereby posing challenges in terms of post-authorisation data collection and data analysis. We believe that the network of population-based Nordic healthcare databases has some characteristics that can help provide important data on these new types of advanced products. In particular, the possibility of very long follow-up periods with a limited loss to follow-up is an important strength. Given the limited source population and slow access to data, a Nordic chimeric antigen receptor redirected T-cell monitoring project should be seen as complementary to other surveillance initiatives.

AB - Following intense research efforts, modulation of the immune system has finally proved to be a viable approach for treating malignant disease. Recently, chimeric antigen receptor redirected T cells have achieved promising outcomes in patients with B-cell malignancies and they are currently also being investigated in other haematological malignancies, solid tumours and viral infections. Compared with traditional biopharmaceuticals, the properties of genetically modified chimeric antigen receptor redirected T-cell therapies differ in many aspects, thereby posing challenges in terms of post-authorisation data collection and data analysis. We believe that the network of population-based Nordic healthcare databases has some characteristics that can help provide important data on these new types of advanced products. In particular, the possibility of very long follow-up periods with a limited loss to follow-up is an important strength. Given the limited source population and slow access to data, a Nordic chimeric antigen receptor redirected T-cell monitoring project should be seen as complementary to other surveillance initiatives.

U2 - 10.1007/s40290-019-00270-7

DO - 10.1007/s40290-019-00270-7

M3 - Journal article

C2 - 31933251

VL - 33

SP - 83

EP - 88

JO - Journal of Pharmaceutical Medicine

JF - Journal of Pharmaceutical Medicine

SN - 0731-7085

IS - 2

ER -

ID: 59260737